Foundation for Sarcoidosis Research   Report issue

Foundation Phase 2
Founded: Chicago IL United States (2000)

Organization Overview

First Clinical Trial
2019
NCT03824392
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Foundation for Sarcoidosis Research

Active Ingredients

Drugs in Phase 2 Trials (1)

Efzofitimod (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Sarcoidosis (Phase 2)

Sarcoidosis, Pulmonary (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1